Endothelin-1 is a key mediator of coronary vasoconstriction in patients with transplant coronary arteriosclerosis

Circulation: Heart Failure

Volumn 2, Issue 5, 2009, Pages 409-416

  Larose, Eric ^a   Behrendt, Dominik ^b   Kinlay, Scott ^c   Selwyn, Andrew P ^c   Ganz, Peter ^d   Fang, James C ^e  

^a LAVAL UNIVERSITY   (Canada)

^b Klinik fur Kardiologie   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Endothelin; Heart transplant; Transplant coronary arteriosclerosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; CYCLO(TRP ASP PRO VAL LEU); CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIN A RECEPTOR; VASODILATOR AGENT;

ADULT; AGED; ARTERY TONE; ARTICLE; BLOOD VESSEL DIAMETER; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; CORONARY VASCULAR RESISTANCE; DISEASE SEVERITY; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; MALE; PRIORITY JOURNAL; RECEPTOR BLOCKING; TRANSPLANT CORONARY ARTERIOSCLEROSIS; VASOMOTOR REFLEX; BLOOD FLOW VELOCITY; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFECT; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MICROCIRCULATION; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; VASCULAR RESISTANCE; VASOCONSTRICTION;

ADULT; AGED; BLOOD FLOW VELOCITY; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; ENDOTHELIN-1; FEMALE; HEART TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROCIRCULATION; MIDDLE AGED; PEPTIDES, CYCLIC; RECEPTOR, ENDOTHELIN A; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 70350457669     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.836759     Document Type: Article

References (46)

1. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report-1998. J Heart Lung Transplant. 1998;17:656-668.
2. Fang JC, Rocco T, Jarcho J, Ganz P, Mudge GH. Noninvasive assessment of transplant-associated arteriosclerosis. Am Heart J. 1998;135:980-987.
3. Shi C, Lee WS, He Q, Zhang D, Fletcher DL Jr, Newell JB, Haber E. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA. 1996;93:4051-4056.
4. Wang Y, Rose PM, Webb ML, Dunn MJ. Endothelins stimulate mitogen-activated protein kinase cascade through either ETA or ETB. Am J Physiol. 1994;267:C1130-C1135.
5. Lerman A, Kubo SH, Tschumperlin LK, Burnett JC Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol. 1992;20:849-853.
6. Okada K, Nishida Y, Murakami H, Sugimoto I, Kosaka H, Morita H, Yamashita C, Okada M. Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts: antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist. Circulation. 1998;97:2346-2351.
7. Ravalli S, Szabolcs M, Albala A, Michler RE, Cannon PJ. Increased immunoreactive endothelin-1 in human transplant coronary artery disease. Circulation. 1996;94:2096-2102.
8. Remuzzi G, Benigni A. Endothelins in the control of cardiovascular and renal function. Lancet. 1993;342:589-593.
9. Ohlstein EH, Arleth A, Bryan H, Elliott JD, Sung CP. The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol. 1992;225:347-350.
10. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, Selwyn AP, Ganz P. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation. 2001;104:1114-1118.
11. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 1998;97:752-756.
12. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO III, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 1999;33:753-758.
13. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant. 2006;25:869-879.
14. Tuzcu EM, Hobbs RE, Rincon G, Bott-Silverman C, De Franco AC, Robinson K, McCarthy PM, Stewart RW, Guyer S, Nissen SE. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation. Insights from intravascular ultrasound. Circulation. 1995;91:1706-1713.
15. Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation. N Engl J Med. 1991;324:1791-1794.
16. Keogh AM, Valantine HA, Hunt SA, Schroeder JS, McIntosh N, Oyer PE, Stinson EB. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant. 1992;11:892-901.
17. Schroeder JS, Gao SZ, Alderman EL, Hunt SA, Johnstone I, Boothroyd DB, Wiederhold V, Stinson EB. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients (see comments). N Engl J Med. 1993;328:164-170.
18. Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D, Suh J, Frei B, Mudge GH, Selwyn AP, Ganz P. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002;359:1108-1113.
19. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al. Effect of pravastatin on outcomes after cardiac transplantation (see comments). N Engl J Med. 1995;333:621-627.
20. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, Stinson EB, Brown BW Jr, Merigan TC, Schroeder JS. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebocontrolled study. Circulation. 1999;100:61-66.
21. Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, Macdonald P, Esmore D, Muller D, Faddy S. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694-2700.
22. Behrendt D, Ganz P, Fang JC. Cardiac allograft vasculopathy. Curr Opin Cardiol. 2000;15:422-429.
23. Fish RD, Nabel EG, Selwyn AP, Ludmer PL, Mudge GH, Kirshenbaum JM, Schoen FJ, Alexander RW, Ganz P. Responses of coronary arteries of cardiac transplant patients to acetylcholine. J Clin Invest. 1988;81:21-31.
24. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051.
25. Pucci AM, Forbes RD, Billingham ME. Pathologic features in long-term cardiac allografts. J Heart Transplant. 1990;9:339-345.
26. Libby P, Zhao DX. Allograft arteriosclerosis and immune-driven angiogenesis. Circulation. 2003;107:1237-1239.
27. Masaki T. Endothelin in vascular biology. Ann N Y Acad Sci. 1994;714:101-108.
28. Fukuchi M, Giaid A. Endothelial expression of endothelial nitric oxide synthase and endothelin-1 in human coronary artery disease. Specific reference to underlying lesion. Lab Invest. 1999;79:659-670.
29. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
30. Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation. 2001;104:864-869.
31. Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA. 1995;92:5244-5248.
32. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434-2440.
33. Sanz MJ, Johnston B, Issekutz A, Kubes P. Endothelin-1 causes P-selectin-dependent leukocyte rolling and adhesion within rat mesenteric microvessels. Am J Physiol. 1999;277:H1823-H1830.
34. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD (P) H oxidase in human endothelial cells. Biochem Biophys Res Commun. 2000;269:713-717.
35. Watschinger B, Sayegh MH, Hancock WW, Russell ME. Up-regulation of endothelin-1 mRNA and peptide expression in rat cardiac allografts with rejection and arteriosclerosis. Am J Pathol. 1995;146:1065-1072.
36. Yamaguchi A, Miniati DN, Hirata K, Hoyt EG, Robbins RC. Ex vivo blockade of endothelin-1 inhibits graft coronary artery disease in a rodent cardiac allograft model. J Heart Lung Transplant. 2002;21:417-424.
37. Aharinejad S, Schafer R, Hofbauer R, Abraham D, Blumer R, Miksovsky A, Traxler H, Pullirsch D, Alexandrowicz R, Taghavi S, Kocher A, Laufer G. Impact of cardiac transplantation on molecular pathology of ET-1, VEGF-C, and mitochondrial metabolism and morphology in dilated versus ischemic cardiomyopathic patients. Transplantation. 2001;72:1043-1049.
38. Ferri C, Properzi G, Tomassoni G, Santucci A, Desideri G, Giuliani AE, Starling RC, Ratliff NB, Cook DJ, McCarthy P, Young JB, Yamani MH. Patterns of myocardial endothelin-1 expression and outcome after cardiac transplantation. Circulation. 2002;105:1768-1771.
39. Weis M, Wildhirt SM, Schulze C, Rieder G, Wilbert-Lampen U, Wolf WP, Arendt RM, Enders G, Meiser BM, von Scheidt W. Endothelin in coronary endothelial dysfunction early after human heart transplantation. J Heart Lung Transplant. 1999;18:1071-1079.
40. Lattmann T, Ortmann J, Horber S, Shaw SG, Hein M, Barton M. Upregulation of endothelin converting enzyme-1 in host liver during chronic cardiac allograft rejection. Exp Biol Med (Maywood). 2006;231:899-901.
41. Kahler J, Ewert A, Weckmuller J, Stobbe S, Mittmann C, Koster R, Paul M, Meinertz T, Munzel T. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol. 2001;38:49-57.
42. Molet S, Furukawa K, Maghazechi A, Hamid Q, Giaid A. Chemokineand cytokine-induced expression of endothelin 1 and endothelin converting enzyme 1 in endothelial cells. J Allergy Clin Immunol. 2000;105:333-338.
43. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Hamaoki M, Kato H, Yazaki Y. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun. 1989;159:1435-1440.
44. Davis SF, Yeung AC, Meredith IT, Charbonneau F, Ganz P, Selwyn AP, Anderson TJ. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation. 1996;93:457-462.
45. Behrendt D, Beltrame J, Hikiti H, Wainstein M, Kinlay S, Selwyn AP, Ganz P, Fang JC. Impact of coronary endothelial function on the progression of cardiac transplant-associated arteriosclerosis: effect of anti-oxidant vitamins C and E. J Heart Lung Transplant. 2006;25:426-433.
46. Gao SZ, Hunt SA, Schroeder JS, Alderman EL, Hill IR, Stinson EB. Early development of accelerated graft coronary artery disease: risk factors and course. J Am Coll Cardiol. 1996;28:673-679.